Eintrag weiter verarbeiten
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 i...
Gespeichert in:
| Zeitschriftentitel: | The Oncologist |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , |
| In: | The Oncologist, 22, 2017, 2, S. 131-138 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Oxford University Press (OUP)
|
| Schlagwörter: |
| author_facet |
Dall, Peter Koch, Thorsten Göhler, Thomas Selbach, Johannes Ammon, Andreas Eggert, Jochen Gazawi, Nidal Rezek, Daniela Wischnik, Arthur Hielscher, Carsten Keitel, Stella Cirrincione, Ursula Hinke, Axel Feisel-Schwickardi, Gabriele Dall, Peter Koch, Thorsten Göhler, Thomas Selbach, Johannes Ammon, Andreas Eggert, Jochen Gazawi, Nidal Rezek, Daniela Wischnik, Arthur Hielscher, Carsten Keitel, Stella Cirrincione, Ursula Hinke, Axel Feisel-Schwickardi, Gabriele |
|---|---|
| author |
Dall, Peter Koch, Thorsten Göhler, Thomas Selbach, Johannes Ammon, Andreas Eggert, Jochen Gazawi, Nidal Rezek, Daniela Wischnik, Arthur Hielscher, Carsten Keitel, Stella Cirrincione, Ursula Hinke, Axel Feisel-Schwickardi, Gabriele |
| spellingShingle |
Dall, Peter Koch, Thorsten Göhler, Thomas Selbach, Johannes Ammon, Andreas Eggert, Jochen Gazawi, Nidal Rezek, Daniela Wischnik, Arthur Hielscher, Carsten Keitel, Stella Cirrincione, Ursula Hinke, Axel Feisel-Schwickardi, Gabriele The Oncologist Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany Cancer Research Oncology |
| author_sort |
dall, peter |
| spelling |
Dall, Peter Koch, Thorsten Göhler, Thomas Selbach, Johannes Ammon, Andreas Eggert, Jochen Gazawi, Nidal Rezek, Daniela Wischnik, Arthur Hielscher, Carsten Keitel, Stella Cirrincione, Ursula Hinke, Axel Feisel-Schwickardi, Gabriele 1083-7159 1549-490X Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1634/theoncologist.2016-0193 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods</jats:title> <jats:p>Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy. Long-term outcome data were obtained in yearly intervals. All analyses were descriptive in nature.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among 3,940 evaluable patients, 26% were elderly (older than 65 years of age). More than half of the population had pN0 tumor stage. Ninety-four percent received chemotherapy: 78% as adjuvant treatment and 14% as neoadjuvant treatment, 2% both. Anthracyclines were administered in 87% and taxanes in 66%. Trastuzumab was stopped prematurely in 9% (because of cardiotoxicity in 3.5%). Recurrence-free survival was 90.0% (95% confidence interval [CI], 88.9%–91.1%) and 82.8% (95% CI, 81.2%–84.4%) after 3 and 5 years, respectively. The corresponding figures for overall survival were 96.8% (95% CI, 96.1%–97.6%) and 90.0% (95% CI, 88.6%–91.4%). Pathological primary tumor size, lymph node involvement, and hormone receptor status had the greatest independent effect on recurrence risk. Cardiac function toxicity of National Cancer Institute common toxicity criteria grade ≥2 and ≥3 was observed in 2.5% and less than 1% of patients, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The maturing follow-up data seem to confirm the beneficial results of trastuzumab treatment for early breast cancer from the randomized studies. Moreover, these findings support use of trastuzumab-based therapy in patients groups less commonly included in the phase III trials (e.g., elderly patients and those with stage I disease).</jats:p> </jats:sec> Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany The Oncologist |
| doi_str_mv |
10.1634/theoncologist.2016-0193 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTYtMDE5Mw |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTYtMDE5Mw |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Oxford University Press (OUP), 2017 |
| imprint_str_mv |
Oxford University Press (OUP), 2017 |
| issn |
1083-7159 1549-490X |
| issn_str_mv |
1083-7159 1549-490X |
| language |
English |
| mega_collection |
Oxford University Press (OUP) (CrossRef) |
| match_str |
dall2017trastuzumabinhumanepidermalgrowthfactorreceptor2positiveearlybreastcancerresultsofaprospectivenoninterventionalstudyonroutinetreatmentbetween2006and2012ingermany |
| publishDateSort |
2017 |
| publisher |
Oxford University Press (OUP) |
| recordtype |
ai |
| record_format |
ai |
| series |
The Oncologist |
| source_id |
49 |
| title |
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_unstemmed |
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_full |
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_fullStr |
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_full_unstemmed |
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_short |
Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_sort |
trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: results of a prospective, noninterventional study on routine treatment between 2006 and 2012 in germany |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1634/theoncologist.2016-0193 |
| publishDate |
2017 |
| physical |
131-138 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Purpose</jats:title>
<jats:p>Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Patients and Methods</jats:title>
<jats:p>Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy. Long-term outcome data were obtained in yearly intervals. All analyses were descriptive in nature.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>Among 3,940 evaluable patients, 26% were elderly (older than 65 years of age). More than half of the population had pN0 tumor stage. Ninety-four percent received chemotherapy: 78% as adjuvant treatment and 14% as neoadjuvant treatment, 2% both. Anthracyclines were administered in 87% and taxanes in 66%. Trastuzumab was stopped prematurely in 9% (because of cardiotoxicity in 3.5%). Recurrence-free survival was 90.0% (95% confidence interval [CI], 88.9%–91.1%) and 82.8% (95% CI, 81.2%–84.4%) after 3 and 5 years, respectively. The corresponding figures for overall survival were 96.8% (95% CI, 96.1%–97.6%) and 90.0% (95% CI, 88.6%–91.4%). Pathological primary tumor size, lymph node involvement, and hormone receptor status had the greatest independent effect on recurrence risk. Cardiac function toxicity of National Cancer Institute common toxicity criteria grade ≥2 and ≥3 was observed in 2.5% and less than 1% of patients, respectively.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusion</jats:title>
<jats:p>The maturing follow-up data seem to confirm the beneficial results of trastuzumab treatment for early breast cancer from the randomized studies. Moreover, these findings support use of trastuzumab-based therapy in patients groups less commonly included in the phase III trials (e.g., elderly patients and those with stage I disease).</jats:p>
</jats:sec> |
| container_issue |
2 |
| container_start_page |
131 |
| container_title |
The Oncologist |
| container_volume |
22 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334575769223170 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:30:30.73Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Trastuzumab+in+Human+Epidermal+Growth+Factor+Receptor+2-Positive+Early+Breast+Cancer%3A+Results+of+a+Prospective%2C+Noninterventional+Study+on+Routine+Treatment+Between+2006+and+2012+in+Germany&rft.date=2017-02-01&genre=article&issn=1549-490X&volume=22&issue=2&spage=131&epage=138&pages=131-138&jtitle=The+Oncologist&atitle=Trastuzumab+in+Human+Epidermal+Growth+Factor+Receptor+2-Positive+Early+Breast+Cancer%3A+Results+of+a+Prospective%2C+Noninterventional+Study+on+Routine+Treatment+Between+2006+and+2012+in+Germany&aulast=Feisel-Schwickardi&aufirst=Gabriele&rft_id=info%3Adoi%2F10.1634%2Ftheoncologist.2016-0193&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334575769223170 |
| author | Dall, Peter, Koch, Thorsten, Göhler, Thomas, Selbach, Johannes, Ammon, Andreas, Eggert, Jochen, Gazawi, Nidal, Rezek, Daniela, Wischnik, Arthur, Hielscher, Carsten, Keitel, Stella, Cirrincione, Ursula, Hinke, Axel, Feisel-Schwickardi, Gabriele |
| author_facet | Dall, Peter, Koch, Thorsten, Göhler, Thomas, Selbach, Johannes, Ammon, Andreas, Eggert, Jochen, Gazawi, Nidal, Rezek, Daniela, Wischnik, Arthur, Hielscher, Carsten, Keitel, Stella, Cirrincione, Ursula, Hinke, Axel, Feisel-Schwickardi, Gabriele, Dall, Peter, Koch, Thorsten, Göhler, Thomas, Selbach, Johannes, Ammon, Andreas, Eggert, Jochen, Gazawi, Nidal, Rezek, Daniela, Wischnik, Arthur, Hielscher, Carsten, Keitel, Stella, Cirrincione, Ursula, Hinke, Axel, Feisel-Schwickardi, Gabriele |
| author_sort | dall, peter |
| container_issue | 2 |
| container_start_page | 131 |
| container_title | The Oncologist |
| container_volume | 22 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods</jats:title> <jats:p>Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy. Long-term outcome data were obtained in yearly intervals. All analyses were descriptive in nature.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among 3,940 evaluable patients, 26% were elderly (older than 65 years of age). More than half of the population had pN0 tumor stage. Ninety-four percent received chemotherapy: 78% as adjuvant treatment and 14% as neoadjuvant treatment, 2% both. Anthracyclines were administered in 87% and taxanes in 66%. Trastuzumab was stopped prematurely in 9% (because of cardiotoxicity in 3.5%). Recurrence-free survival was 90.0% (95% confidence interval [CI], 88.9%–91.1%) and 82.8% (95% CI, 81.2%–84.4%) after 3 and 5 years, respectively. The corresponding figures for overall survival were 96.8% (95% CI, 96.1%–97.6%) and 90.0% (95% CI, 88.6%–91.4%). Pathological primary tumor size, lymph node involvement, and hormone receptor status had the greatest independent effect on recurrence risk. Cardiac function toxicity of National Cancer Institute common toxicity criteria grade ≥2 and ≥3 was observed in 2.5% and less than 1% of patients, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The maturing follow-up data seem to confirm the beneficial results of trastuzumab treatment for early breast cancer from the randomized studies. Moreover, these findings support use of trastuzumab-based therapy in patients groups less commonly included in the phase III trials (e.g., elderly patients and those with stage I disease).</jats:p> </jats:sec> |
| doi_str_mv | 10.1634/theoncologist.2016-0193 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTYzNC90aGVvbmNvbG9naXN0LjIwMTYtMDE5Mw |
| imprint | Oxford University Press (OUP), 2017 |
| imprint_str_mv | Oxford University Press (OUP), 2017 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275 |
| issn | 1083-7159, 1549-490X |
| issn_str_mv | 1083-7159, 1549-490X |
| language | English |
| last_indexed | 2024-03-01T14:30:30.73Z |
| match_str | dall2017trastuzumabinhumanepidermalgrowthfactorreceptor2positiveearlybreastcancerresultsofaprospectivenoninterventionalstudyonroutinetreatmentbetween2006and2012ingermany |
| mega_collection | Oxford University Press (OUP) (CrossRef) |
| physical | 131-138 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Oxford University Press (OUP) |
| record_format | ai |
| recordtype | ai |
| series | The Oncologist |
| source_id | 49 |
| spelling | Dall, Peter Koch, Thorsten Göhler, Thomas Selbach, Johannes Ammon, Andreas Eggert, Jochen Gazawi, Nidal Rezek, Daniela Wischnik, Arthur Hielscher, Carsten Keitel, Stella Cirrincione, Ursula Hinke, Axel Feisel-Schwickardi, Gabriele 1083-7159 1549-490X Oxford University Press (OUP) Cancer Research Oncology http://dx.doi.org/10.1634/theoncologist.2016-0193 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Purpose</jats:title> <jats:p>Trastuzumab is part of the standard treatment in patients with human epidermal growth factor receptor 2-positive early breast cancer in addition to (neo)adjuvant chemotherapy. This German prospective noninterventional study, which included major patient cohorts underrepresented in the pivotal randomized studies, examined the generalizability of the results of those studies.</jats:p> </jats:sec> <jats:sec> <jats:title>Patients and Methods</jats:title> <jats:p>Between 2006 and 2012, 4,027 patients were enrolled and treated with trastuzumab; they were unselected regarding age or concomitant/sequential adjuvant chemotherapy. Long-term outcome data were obtained in yearly intervals. All analyses were descriptive in nature.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Among 3,940 evaluable patients, 26% were elderly (older than 65 years of age). More than half of the population had pN0 tumor stage. Ninety-four percent received chemotherapy: 78% as adjuvant treatment and 14% as neoadjuvant treatment, 2% both. Anthracyclines were administered in 87% and taxanes in 66%. Trastuzumab was stopped prematurely in 9% (because of cardiotoxicity in 3.5%). Recurrence-free survival was 90.0% (95% confidence interval [CI], 88.9%–91.1%) and 82.8% (95% CI, 81.2%–84.4%) after 3 and 5 years, respectively. The corresponding figures for overall survival were 96.8% (95% CI, 96.1%–97.6%) and 90.0% (95% CI, 88.6%–91.4%). Pathological primary tumor size, lymph node involvement, and hormone receptor status had the greatest independent effect on recurrence risk. Cardiac function toxicity of National Cancer Institute common toxicity criteria grade ≥2 and ≥3 was observed in 2.5% and less than 1% of patients, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The maturing follow-up data seem to confirm the beneficial results of trastuzumab treatment for early breast cancer from the randomized studies. Moreover, these findings support use of trastuzumab-based therapy in patients groups less commonly included in the phase III trials (e.g., elderly patients and those with stage I disease).</jats:p> </jats:sec> Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany The Oncologist |
| spellingShingle | Dall, Peter, Koch, Thorsten, Göhler, Thomas, Selbach, Johannes, Ammon, Andreas, Eggert, Jochen, Gazawi, Nidal, Rezek, Daniela, Wischnik, Arthur, Hielscher, Carsten, Keitel, Stella, Cirrincione, Ursula, Hinke, Axel, Feisel-Schwickardi, Gabriele, The Oncologist, Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany, Cancer Research, Oncology |
| title | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_full | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_fullStr | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_full_unstemmed | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_short | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| title_sort | trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: results of a prospective, noninterventional study on routine treatment between 2006 and 2012 in germany |
| title_unstemmed | Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1634/theoncologist.2016-0193 |